BCTX BriaCell Therapeutics Corp
Price (delayed)
$0.5125
Market cap
$9.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
$8.44M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Highlights
The EPS has surged by 69% year-on-year and by 54% since the previous quarter
The net income has soared by 67% YoY and by 52% QoQ
BriaCell Therapeutics's quick ratio has plunged by 99% YoY and by 91% from the previous quarter
Key stats
What are the main financial stats of BCTX
Market
Valuations
Earnings
Shares outstanding
18.28M
Market cap
$9.37M
Enterprise value
$8.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$20.8M
EBITDA
-$20.78M
Free cash flow
-$31.01M
Per share
Balance sheet
Liquidity
EPS
-$0.37
Free cash flow per share
-$1.94
Book value per share
-$0.37
Revenue per share
$0
TBVPS
$0.38
Total assets
$6.2M
Total liabilities
$12.44M
Debt
$0
Equity
-$5.97M
Working capital
-$1.23M
Debt to equity
0
Current ratio
0.82
Quick ratio
0.14
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.6%
Return on equity
N/A
Return on invested capital
-1,070.2%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCTX stock price
How has the BriaCell Therapeutics stock price performed over time
Intraday
-8.56%
1 week
-24.63%
1 month
-8.38%
1 year
-91.57%
YTD
-91.24%
QTD
-55.04%
Financial performance
How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.27M
Net income
-$6.04M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 70% YoY and by 11% QoQ
The net income has soared by 67% YoY and by 52% QoQ
Growth
What is BriaCell Therapeutics's growth rate over time
Valuation
What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 69% year-on-year and by 54% since the previous quarter
The company's equity rose by 26% QoQ
Efficiency
How efficient is BriaCell Therapeutics business performance
BriaCell Therapeutics's ROIC has decreased by 46% from the previous quarter
BCTX's ROA is up by 35% since the previous quarter and by 26% year-on-year
Dividends
What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCTX.
Financial health
How did BriaCell Therapeutics financials performed over time
The total assets is 50% smaller than the total liabilities
BriaCell Therapeutics's quick ratio has plunged by 99% YoY and by 91% from the previous quarter
BriaCell Therapeutics's current ratio has shrunk by 96% YoY and by 73% QoQ
The debt is 100% greater than the equity
The company's equity rose by 26% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.